Can-Fite Biopharma Profit Margin

Can-Fite Biopharma (CANF) currently reports a profit margin of -2426.67% as of December 2025. That compares with -1168.99% in the prior-year period — down 107.6% year over year. That is below the Healthcare sector average of 13.76%. Use the charts on this page to explore Can-Fite Biopharma's profit margin history and peer comparisons.

Can-Fite Biopharma's profit margin decreased from -1168.99% to -2426.67% — a 107.6% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Can-Fite Biopharma's profit margin of -2426.67% is lower than the Healthcare sector average of 13.76%. That is roughly 17735.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Can-Fite Biopharma's current -2426.67% should be judged against Healthcare norms (sector average: 13.76%) and against CANF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2426.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Can-Fite Biopharma, and consider following CANF for alerts when major investors trade the stock.